⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Fig. 5 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer

Sarat Chandarlapaty Maura N. Dickler José Alejandro Pérez Fidalgo Rafael Villanueva-Vázquez Jennifer M. Giltnane Mary Gates Ching‐Wei Chang Sravanthi Cheeti Jill Fredrickson Xiaojing Wang Ann Collier Heather M. Moore Ciara Metcalfe Jennifer Lauchle Eric W. Humke Aditya Bardia

View at Publisher

Ask AI

Bookmark

Share

Abstract

Supplementary Fig. S5. Kaplan-Meier estimate of progression-free survival for patients with and without ESR1 mutations in baseline ctDNA samples collected from the 1400 mg dose group. ESR1 data was available for 36 of 36 patients dosed at 1400 mg.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chandarlapaty et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875237e7 https://doi.org/10.1158/1078-0432.27032071

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Fig. 5 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024
2Supplementary Fig. 4 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024
3Supplementary Fig. 4 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024
4Supplementary Fig. 3 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024
5Supplementary Fig. 3 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024

More related papers

Supplementary Fig. 6 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024
Supplementary Fig. 6 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024
Supplementary Data 1 from An open-label phase I study of GDC-0927 in postmenopausal women with locally advanced or metastatic estrogen receptor positive breast cancer2024